TRAW Traws Pharma, Inc.

NEUTRAL Impact: 3/10 DEFA14A
Horizon weeks Filed May 29, 2026 Processed 15d 1h ago SEC 0001104659-26-067949
Proxy solicitation materials
Latest settled — T+5d
TRAW ▼ -0.68% at T+5d
NEUTRAL call ✗ call lost -0.68% · α vs SPY -0.39% · entry $1.46 → $1.45
Next anchor: T+20d in 16d
Currently $1.28 · -12.33% from $1.46 entry
Entry anchored
May 28, 05:55 PM ET
via Databento tick
T+1d
+0.68%
call +0.68% · α +0.41%
$1.47
settled 12d ago
T+5d
-0.68%
call -0.68% · α -0.39%
$1.45
settled 8d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Traws Pharma filed DEFA14A additional definitive proxy soliciting materials for its 2026 Annual Meeting scheduled for July 8, 2026. The filing notifies shareholders of five proposals: election of seven directors, amendment to the 2021 Incentive Compensation Plan to increase shares by 2,000,000, ratification of KPMG as auditor, approval of share issuance upon exercise of Series B and C Warrants issued under an April 15, 2026 Securities Purchase Agreement, and approval of adjournment if needed. The board recommends a 'For' vote on all items. This is a routine proxy notice with no material financial data or activist campaign disclosed.

Actionable Insight

This is a routine proxy notice with no material new information. Monitor the annual meeting outcome for approval of the warrant-related share issuance, which could lead to modest dilution if exercised. No immediate trading action warranted.

Key Facts

  • Annual Meeting scheduled for July 8, 2026, with virtual attendance option
  • Seven director nominees proposed for election
  • Amendment to 2021 Incentive Compensation Plan seeks to increase authorized shares by 2,000,000
  • Proposal to approve issuance of shares upon exercise of Series B and C Warrants from April 15, 2026 Securities Purchase Agreement
  • KPMG LLP proposed as independent auditor for fiscal year ending December 31, 2026
  • Board recommends 'For' vote on all five proposals
  • Voting deadline is July 7, 2026 at 11:59 PM ET

Financial Impact

No financial figures disclosed in this filing. The compensation plan amendment would increase authorized shares by 2,000,000, but no dollar amounts are provided.

dilution

Risk Factors

  • Potential dilution from 2,000,000 additional shares under the compensation plan amendment
  • Potential dilution from exercise of Series B and C Warrants if Proposal 4 is approved

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-067949
Document: 0001104659-26-067949-index-headers.html0001104659-26-067949
Document: 0001104659-26-067949-index.html0001104659-26-067949
Document: 0001104659-26-067949.txt0001104659-26-067949
14 reports for TRAW
Performance horizon
100% Hit rate 7 of 7 directional calls best @ T+20▲ +42.15%Apr 15, 2026
Filters
Rows
Reports for TRAW — sortable, filterable
Type Now
Jun 12, 2026
today
8-K
BEARISH ★ 7/10
$1.29 awaiting T+5awaiting T+5$1.28 (+0.78%)
May 29, 2026
15d ago
DEFA14A
NEUTRAL ★ 3/10
$1.46 $1.45▼ −0.68%▼ −0.39%$1.28 (−12.33%)
May 27, 2026
17d ago
8-K
NEUTRAL ★ 4/10
$1.53 $1.42▼ −7.19%▼ −8.40%$1.28 (−16.34%)
May 26, 2026
17d ago
8-K
NEUTRAL ★ 3/10
$1.53 $1.45▼ −5.23%▼ −5.70%$1.28 (−16.34%)
May 22, 2026
22d ago
424B5
BEARISH ★ 7/10
$1.49 $1.47▲ +1.34%▲ +3.02%$1.28 (+14.09%)
May 18, 2026
26d ago
EFFECT
BEARISH ★ 7/10
$1.76 $1.58▲ +10.23%▲ +11.85%$1.28 (+27.27%)
May 15, 2026
29d ago
8-K
BEARISH ★ 7/10
$1.88 $1.49▲ +20.74%▲ +21.71%$1.28 (+31.91%)
May 15, 2026
29d ago
Press Release
MIXED ★ 5/10
$1.88 $1.49▼ −20.74%▼ −21.71%$1.28 (−31.91%)
May 8, 2026
5w ago
S-3
BEARISH ★ 8/10
$2.02 $1.76▲ +12.87%▲ +12.79%$1.28 (+36.63%)
May 8, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$2.18 $1.63▼ −25.23%▼ −26.69%$1.28 (−41.28%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (46h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access